Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia.

ABSTRACT:

Background

Sleep disturbance is a core feature of post-traumatic stress disorder (PTSD). Given the relationship between sleep disturbance and PTSD, there has been a relative paucity of studies examining the potential therapeutic impact of using pharmacotherapy to target sleep disturbance in patients with PTSD. Eszopiclone (ESZ) is a non-benzodiazepine y-aminobutyric acid-A receptor agonist indicated for the treatment of sleep and may affect sleep in patients with PTSD.

Aim

To evaluate the efficacy of ESZ vs placebo (PBO) for patients with PTSD and insomnia.

Methods

The study was a 12-wk, double blind, randomized controlled trial with 3 mg of ESZ (n = 13) or PBO (n = 12).

Results

Patients in both arms experienced significant improvement in P

SUBMITTER: Dowd SM 

PROVIDER: S-EPMC7099286 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature